新辅助化疗治疗晚期卵巢癌的临床疗效评价

  目的：对新辅助化疗治疗Ⅲ~Ⅳ期晚期卵巢癌的疗效进行评价。方法：回顾性分析204例晚期卵巢癌患者的诊治情况。2003年之前收治的99例Ⅲ~Ⅳ期卵巢癌患者为A组，行一期手术治疗。2003年之后收治的105例Ⅲ~Ⅳ期卵巢癌患者为B组，其中有39例在进行1~3疗程新辅助化疗的基础上行肿瘤细胞减灭术，为B1组，另66例行一期手术治疗，为B2组。入组患者术后均行6~8疗程卡铂、环磷酰胺联合干扰素的化疗。结果：B1组患者围手术期一般状况优于B2组（P0.05）。B组患者三年生存率高于A组（P0.05）。结论：对Ⅲ~Ⅳ期的晚期卵巢癌患者而言，有选择性的应用新辅助化疗可以提高其手术满意率、围手术期一般状况以及三年生存率。满意的肿瘤细胞减灭术即残留病灶<2cm可以提高晚期卵巢癌患者的生存率。

Clinical Effect Analysis of the Neoadjuvant Chemotherapy on Advanced Ovarian Carcinoma

Objective To evaluate the effects of neoadjuvant chemotherapy in adavanced ovarian carcinoma.Methods Retrospective analysis of 204 patients with advanced ovarian carcinoma was performed.Patients were divided into two groups.Before 2003,all patients received primary debulking surgery were classified as control group(A group).After 2003,patients surgically evaluated to receive primary chemotherapy(B1 group) or primary debulking surgery(B2 group) were classified as research group(B group).All patients in our reaserch received tumor debulking surgery followed by 6~8 cycles of platinum based chemotherapy,combined with cyclophosphamide and interferon.Results The B1 group had a better performance surround the surgery than that of the B2 group(P < 0.05).The optimal operation rate of the B group was significantly higher than that of the A group(P < 0.05).The optimal operation rate and 3-year survival rate between group B1 and B2 was not statistically different(P > 0.05).The 3-year survival rate between group B was higher than group A which the difference was statistically difference(P < 0.05).Conclusion Higher optimal operation rate,better performance surround the surgery and longer 3-year survival rate can be achieved in patients with advanced ovarian carcinoma by the selective use of neoadjuvant chemotherapy.